Journal of Rheumatology最新文献

{"title":"Priority Setting of Physical Activity Barriers and Facilitators Among Individuals With Rheumatoid Arthritis: A Nominal Group Technique Study.","authors":"Manuel Ester, Kiran Dhiman, Racheal Githumbi, Melissa Sipley, Kamala Adhikari Dahal, Claire E H Barber","doi":"10.3899/jrheum.2025-0191","DOIUrl":"10.3899/jrheum.2025-0191","url":null,"abstract":"<p><strong>Objective: </strong>To (1) understand key physical activity (PA) determinants for individuals with rheumatoid arthritis (RA), and (2) map determinants using the Behavior Change Wheel (BCW) to guide theory-driven intervention development.</p><p><strong>Methods: </strong>A patient-centered nominal group technique (NGT) approach was used, with recruitment through purposive sampling from past research participants. After self-reporting demographics and PA, participants attended NGT sessions consisting of idea generation, sharing, and refinement through discussion. Researchers combined PA-determinant lists across sessions using content analysis. Using a survey, participants rated the importance of each determinant from 1 to 9. Theoretical mapping was completed with the most important 2 out of 3 determinants using the BCW.</p><p><strong>Results: </strong>Fourteen individuals participated across 3 sessions. The mean age was 58.1 (SD 13.4) years, with a mean 20.0 (SD 21.8) years with RA. Participants were 86% female, 79% White, and 86% had some university/college education. All participants were physically active, with a mean Godin Leisure-Time Exercise Questionnaire (GLTEQ) leisure score index of 43.3 (SD 18.4; < 14 = insufficiently active, 14-24 = moderately active, > 24 = active). The 22 PA barriers and 25 facilitators fell into 4 categories: personal, social, physical, and environmental. The top 3 barriers (importance: 7.1-7.4/9) were unpredictable fluctuations, fatigue, and lack of RA-specific PA knowledge. The top 3 facilitators (importance: 7.6-7.9/9) were motivation to maintain function, knowledge to tailor PA, and PA self-confidence. Theoretical mapping led to 3 capability-related, 6 opportunity-related, and 4 motivation-related determinants.</p><p><strong>Conclusion: </strong>Our study highlighted key PA determinants related to capability, opportunity, and motivation. Interventions may target skills (capability), social influences (opportunity), and beliefs about capabilities (motivation) to increase PA in individuals with RA.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"979-987"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation as a Treatment Target in Hand Osteoarthritis: A Review of Previous Studies and Future Perspectives.","authors":"Ida K Haugen, Marthe Gløersen, Elisabeth Mulrooney, Alexander Mathiessen","doi":"10.3899/jrheum.2025-0206","DOIUrl":"10.3899/jrheum.2025-0206","url":null,"abstract":"<p><p>Historically, osteoarthritis (OA) was considered a noninflammatory joint disease, distinct from systemic inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. However, observational studies on hand OA have shown that synovitis is common and is associated with both pain and disease progression. Hence, targeting synovitis in hand OA could provide clinical benefits in terms of symptom relief and disease modification. Conflicting results have been found in several previous studies that have tested the efficacy of various antiinflammatory treatments, including oral and topical nonsteroidal antiinflammatory drugs (NSAIDs), oral and intraarticular corticosteroids, colchicine, and synthetic and biologic disease-modifying antirheumatic drugs (DMARDs). To date, prednisolone and methotrexate have shown the most promising results. Several ongoing studies, especially those investigating intraarticular antiinflammatory therapies, are expected to provide valuable insights for clinical practice.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"966-971"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Uncommon Mimic of Spondyloarthritis.","authors":"Shaoyu Zheng, Zhuangyong Xu, Guangzhou Du, Yukai Wang","doi":"10.3899/jrheum.2025-0748","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0748","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choice of biologic immunotherapy for psoriasis or psoriatic arthritis not associated with risk of major adverse cardiac events.","authors":"Jack Geiger, Bonit Gill, Jean Liew, Michael Putman, Shikha Singla","doi":"10.3899/jrheum.2025-0446","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0446","url":null,"abstract":"<p><strong>Objective: </strong>Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk of major adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardial infarction (MI), and cerebrovascular accident (CVA). Biologic disease modifying antirheumatic drugs (bDMARDs) may reduce cardiovascular risk, however, whether MACE risk differs by bDMARD class for this population is unknown.</p><p><strong>Methods: </strong>Using data from TriNetX database, we identified patients with PsO/PsA who were new bDMARD users, including tumor necrosis factor alpha inhibitors (TNFi), interleukin-17A inhibitors (IL17i), interleukin-23 inhibitors (IL-23i), or interleukin-12/23 inhibitors (IL-12/23i). Time-dependent risk for MACE was calculated using weighted multinomial Cox proportional hazards regression with TNF exposure as the referent. Additional analyses evaluated components of the primary outcome and baseline cardiovascular disease. A negative control outcome was used to assess bias.</p><p><strong>Results: </strong>We identified 32,758 patients with PsO/PsA who were new bDMARD users. Patients had PsO/PsA for a mean of 3.5 years (SD 4.5) prior to starting a biologic, the most common being TNFi (62.9%) followed by IL-17i (15.4%), IL-23i (10.7%), and IL12/23i (10.7%). In weighted multinomial Cox proportional hazards regression, the adjusted risk of MACE was similar for IL-17A inhibitors (aHR 0.98, 95% CI 0.73-1.32), IL-23 inhibitors (aHR 0.84, 95% CI 0.54-1.31), and IL-12/23 inhibitors (aHR 1.08, 95% CI 0.80-1.47) as compared to TNFi. Subset analyses supported the primary analysis. Negative control outcomes suggested adequate control of biases confounding.</p><p><strong>Conclusion: </strong>MACE risk does not significantly differ across bDMARD classes in PsO/PsA patients. Therefore, cardiovascular risk should not guide biologic selection in this population.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drs. Queiro and Braña reply.","authors":"Rubén Queiro, Ignacio Braña","doi":"10.3899/jrheum.2025-0751","DOIUrl":"10.3899/jrheum.2025-0751","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"1068-1069"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trust in Health Information Sources Among Patients With Systemic Lupus Erythematosus in the Social Networking Era: The TRUMP2-SLE Study.","authors":"Takanori Ichikawa, Dai Kishida, Yasuhiro Shimojima, Nobuyuki Yajima, Nao Oguro, Ryusuke Yoshimi, Natsuki Sakurai, Chiharu Hidekawa, Ken-Ei Sada, Yoshia Miyawaki, Keigo Hayashi, Kenta Shidahara, Yuichi Ishikawa, Yoshiki Sekijima, Noriaki Kurita","doi":"10.3899/jrheum.2024-1088","DOIUrl":"10.3899/jrheum.2024-1088","url":null,"abstract":"<p><strong>Objective: </strong>The growing use of social networking services (SNS) has affected how patients with systemic lupus erythematosus (SLE) access health information, potentially influencing their interaction with healthcare providers. This study aimed to examine patients' preferences, actual use, and trust in various health information sources, along with the factors influencing the trust among patients with SLE.</p><p><strong>Methods: </strong>A multicenter, cross-sectional survey was conducted from June 2020 to August 2021, involving 510 Japanese adults with SLE. Participants reported their preferred and actual sources of health information, including SNS, and their level of trust in these sources. Modified Poisson regression was used to analyze factors influencing trust, including internet usage and health literacy (HL; functional, communicative, and critical).</p><p><strong>Results: </strong>Most respondents (98.2%) expressed trust in doctors, whereas trust in websites and blogs (52%) and SNS (26.8%) was lower. Despite this, the internet was the most frequent initial source of health information (45.3%), encompassing medical institution websites, patient blogs, X (formerly known as Twitter), and Instagram. Longer internet usage periods were associated with a greater trust in websites and blogs and SNS. Higher functional HL was correlated with an increased trust in doctors but decreased trust in homepages/blogs and SNSs. Higher communicative HL was linked to a greater trust in doctors, websites, and blogs.</p><p><strong>Conclusion: </strong>Although many patients with SLE initially seek health information online, they prefer to consult rheumatologists. Internet usage duration and multidimensional HL influence trust in online sources. Healthcare providers should consider these factors when disseminating health information and engaging with patients.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"1005-1012"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Spondyloarthritis in Patients With Inflammatory Bowel Disease Receiving Treatment With Biologics or Janus Kinase Inhibitors.","authors":"Young-Eun Kim, Soo Min Ahn, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park, Seokchan Hong","doi":"10.3899/jrheum.2024-1279","DOIUrl":"10.3899/jrheum.2024-1279","url":null,"abstract":"<p><strong>Objective: </strong>To detect spondyloarthritis (SpA) and evaluate risk factors in patients with inflammatory bowel disease (IBD) during biologic or Janus kinase inhibitor (JAKi) treatment.</p><p><strong>Methods: </strong>This was a retrospective cohort study of patients with IBD receiving biologics or JAKi, excluding prior SpA cases. We identified patients who developed musculoskeletal (MSK) symptoms during IBD treatment. SpA was diagnosed after a clinical evaluation by a rheumatologist alongside imaging analysis of conventional radiographs and HLA-B27 determination. Magnetic resonance imaging of the sacroiliac joints was performed only in cases where the conventional radiograph was inconclusive.</p><p><strong>Results: </strong>Of 1649 patients with IBD receiving biologic or JAKi treatment (Crohn disease: 1335; ulcerative colitis [UC]: 314), 96 (5.8%) were excluded due to a prior SpA diagnosis. Among the remaining 1553 patients, 106 (6.8%) developed MSK symptoms during IBD treatment, and 30 (1.9%) were diagnosed with SpA (axial: 20; peripheral: 10) during the follow-up (median 5.2 [IQR 3.4-7.5] years). Risk factors for SpA in these patients included a partial Mayo score for UC at the time of onset of MSK symptoms (hazard ratio [HR] 1.57; <i>P</i> = 0.03) and HLA-B27 positivity (HR 3.70; <i>P</i> = 0.004). As well as IBD treatment, 23/30 (77%) patients with SpA used nonsteroidal antiinflammatory drugs (NSAIDs). IBD disease activity did not worsen during treatment, regardless of NSAID use.</p><p><strong>Conclusion: </strong>During a median follow-up of 5.2 years, 6.8% of patients with IBD undergoing biologic or JAKi treatment developed MSK symptoms, with one-third subsequently diagnosed with SpA. HLA-B27 positivity and higher UC disease activity were associated with an increased risk of SpA.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study.","authors":"Hermine I Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, Simone Appenzeller, Vyacheslav Chasnyk, Thomas Griffin, Carmen Navarrete Suarez, Sheila Knupp-Oliveira, Andrew Zeft, Yonatan Butbul Aviel, Deirdre De Ranieri, Beth S Gottlieb, Deborah M Levy, C Egla Rabinovich, Clóvis Artur Silva, Yury Spivakovsky, Yosef Uziel, Sarah Ringold, Xie L Xu, Jocelyn H Leu, Edwin Lam, Yuhua Wang, Daniel J Lovell, Alberto Martini, Nicolino Ruperto","doi":"10.3899/jrheum.2024-0298.C1","DOIUrl":"10.3899/jrheum.2024-0298.C1","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"1069"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cumulative Incidence of Cancer Screening for Breast, Cervical, Prostate, and Colorectal Cancer in Patients With Rheumatoid Arthritis.","authors":"Rebecca T Brooks, Cassondra A Hulshizer, Andrew C Hanson, John M Davis, Vanessa L Kronzer, Elena Myasoedova, Cynthia S Crowson","doi":"10.3899/jrheum.2025-0190","DOIUrl":"10.3899/jrheum.2025-0190","url":null,"abstract":"<p><strong>Objective: </strong>To determine the incidence of breast, cervical, prostate, and colorectal cancer screening in patients with rheumatoid arthritis (RA) vs matched non-RA comparators.</p><p><strong>Methods: </strong>We performed a retrospective, matched cohort study of patients with and without RA living in an 8-county region of southern Minnesota on January 1, 2015. Through review of medical records, patients who fulfilled either the 1987 American College of Rheumatology (ACR) or 2010 ACR/European Alliance of Associations for Rheumatology classification criteria for RA were identified. Patients with RA were matched 1:1 to non-RA comparators on age, sex, and county of residence. Cancer screening was determined from review of the US Preventative Task Force recommendations. Cumulative incidence of cancer screening was estimated accounting for the competing risk of death, and Cox proportional hazard models adjusted for age, smoking, and race assessed for the risk of delay.</p><p><strong>Results: </strong>The study included 1614 patients with RA and 1597 comparators without RA (mean age 63 years, 71% female). At 5-years of follow-up, 51.6% (95% CI 47.9-55.6) of the RA cohort had cervical cancer screening compared to 58.2% (95% CI 54.5-62.2) in the non-RA cohort. After adjusting for age, smoking, and race, RA was associated with decreased cervical cancer screening (adjusted hazard ratio [aHR] 0.83, 95% CI 0.72-0.96). RA was not significantly associated with a decrease in breast (aHR 0.98, 95% CI 0.87-1.10), prostate (aHR 0.99, 95% CI 0.74-1.34), or colorectal (aHR 1.04, 95% CI 0.93-1.16) cancer screening.</p><p><strong>Conclusion: </strong>Women with RA were more likely to experience delayed cervical cancer screening. Increased diligence by healthcare providers to ensure cervical cancer screening in patients with RA is important to reduce the morbidity and mortality seen in these patients.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"988-996"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 Annual Meeting.","authors":"Dafna D Gladman, Wilson Bautista-Molano, Denis Poddubnyy, William Tillett, Alice B Gottlieb","doi":"10.3899/jrheum.2025-0862","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0862","url":null,"abstract":"<p><p>The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting was held from July 11 to July 13, 2024, in Seattle, Washington, USA, and was attended by 256 rheumatologists, dermatologists, trainees, patient research partners, patient organization representatives, industry partners, and others. The meeting featured several workshops on various topics including epidemiology, new educational initiatives, use of artificial intelligence for both education and clinical management of disease, use of magnetic resonance imaging in the diagnosis and management of psoriatic disease (PsD), and many more. Young-GRAPPA held a workshop and business meeting about their projects, and many of the young GRAPPiAns contributed as coauthors of the articles in this supplement. Debates focused on whether clinical enthesitis indices reflect true enthesitis and whether they should be discontinued, and whether musculoskeletal symptoms in PsD should be managed by dermatologists or rheumatologists. Here we provide an overview of the features of the GRAPPA 2024 annual meeting and introduce the manuscripts published together in this supplement as a meeting report.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}